Louisiana 2013 Regular Session

Louisiana House Bill HB356

Introduced
4/8/13  
Refer
4/8/13  

Caption

Defines compounded pharmacy-generated product

Impact

The enactment of HB 356 is expected to harmonize state pharmacy laws with modern practices surrounding compounded products. It is a crucial step toward ensuring that pharmacists have a clear understanding of the scope of their operations, potentially leading to improved safety standards in the preparation and distribution of compounded drugs. Additionally, by defining these terms at the state level, the bill aligns Louisiana's pharmacy practices with national standards, which fosters a more consistent regulatory environment. As a result, patients may benefit from better access to compounded medications that meet their specific health needs.

Summary

House Bill 356, introduced by Representative LeBas, serves to clarify the definitions pertinent to the regulation of compounded pharmacy-generated products within Louisiana's pharmacy legislation. This bill seeks to provide a formal definition for what constitutes a compounded pharmacy-generated product, which is described as a drug prepared for distribution by a pharmacy as per established regulatory rules. By codifying this definition, the bill aims to enhance clarity and compliance within the industry, thus aiding pharmacists in better understanding their legal responsibilities and operational parameters regarding compounded products.

Sentiment

The sentiment around HB 356 appears to be generally positive, with many stakeholders, including pharmacists and pharmacy regulators, viewing the bill as a necessary update to existing laws. By addressing the definition of compounded pharmacy-generated products, the bill is seen as a proactive approach to minimizing ambiguities in pharmacy practice, which resonates well within the healthcare community. Nevertheless, there may be minor concerns regarding the implications of regulatory changes on smaller pharmacies' operational flexibility, although these were not prominently discussed in the available materials.

Contention

While there is a broad consensus on the need to define compounded pharmacy-generated products, potential points of contention may arise regarding how strictly such definitions will be enforced and how they align with existing regulations governing pharmacy practices. Some in the pharmacy field could argue for more expansive definitions or additional regulations to ensure patient safety, while others may contend that overly stringent definitions could limit pharmacists' ability to adapt and respond to patient needs. However, the fundamental agreement on the necessity of clear definitions indicates that significant opposition may be minimal.

Companion Bills

LA HB674

Replaced by Provides relative to pharmacy-generated drugs

Similar Bills

CA AB913

Pharmacy benefit managers.

CA SB362

Chain community pharmacies: quotas.

LA HB432

Provides for the regulation of pharmacy services administrative organizations (OR +$88,000 SG EX See Note)

MS HB1125

Pharmacy services; prohibit insurers and PBMs from requiring persons to obtain exclusively through pharmacies that they own.

LA HB387

Provides for the regulation of pharmacy services administrative organizations

CA AB401

Pharmacy: remote dispensing site pharmacy: telepharmacy: shared clinic office space.

CA AB690

Pharmacies: relocation: remote dispensing site pharmacy: pharmacy technician: qualifications.

AR SB593

To Amend The Arkansas Pharmacy Benefits Manager Licensure Act; And To Create The Pharmacy Services Administrative Organization Act.